The release of Ca 2ϩ from intracellular stores mediated by inositol 1,4,5-trisphosphate binding to inositol 1,4,5-trisphosphate receptors is a ubiquitous process important for control over a diverse array of physiological processes (1-3) . The inositol 1,4,5-trisphosphate receptor (InsP 3 R) 3 family is encoded by three genes, resulting in the expression of three distinct proteins with molecular mass of ϳ300 kDa, named InsP 3 R-1, InsP 3 R-2, and InsP 3 R-3 (4 -6). The pivotal importance of individual InsP 3 R subtypes, in particular physiological processes, is highlighted by the genetic ablation of individual InsP 3 R types (7-9). Additional diversity exists at the protein level by the expression of several splice variants, particularly of the InsP 3 R-1 and InsP 3 R-2 (10 -12).
The release of Ca 2ϩ from intracellular stores mediated by inositol 1,4,5-trisphosphate binding to inositol 1,4,5-trisphosphate receptors is a ubiquitous process important for control over a diverse array of physiological processes (1) (2) (3) . The inositol 1,4,5-trisphosphate receptor (InsP 3 R) 3 family is encoded by three genes, resulting in the expression of three distinct proteins with molecular mass of ϳ300 kDa, named InsP 3 R-1, InsP 3 R-2, and InsP 3 R-3 (4 -6). The pivotal importance of individual InsP 3 R subtypes, in particular physiological processes, is highlighted by the genetic ablation of individual InsP 3 R types (7) (8) (9) . Additional diversity exists at the protein level by the expression of several splice variants, particularly of the InsP 3 R-1 and InsP 3 R-2 (10 -12) .
The functional protein consists of four individual InsP 3 R monomers and can exist in both homo-and heterotetrameric forms (13) (14) (15) . The domain organization for the InsP 3 R family is well established, with the linear structure divided into three general regions. The InsP 3 binding core is toward the N terminus and was originally identified by mutagenesis studies to consist of a stretch of dispersed, positively charged amino acids critical for InsP 3 binding (16, 17) . This observation indicated the importance of the three-dimensional structure of the binding pocket in coordinating the negatively charged phosphate groups of InsP 3 , a proposal that was recently supported by solving the crystal structure of the InsP 3 R binding core (18) .
The ion-conducting pore of the InsP 3 R is toward the extreme C terminus of the protein. This region, termed the "channel domain," is predicted to span the endoplasmic reticulum membrane six times (19, 20) and contains a motif between the fifth and sixth putative transmembrane span, which is conserved in potassium and calcium channels (GVGD) and has subsequently been demonstrated to constitute the ion-conducting pore of the InsP 3 R (20) . Whereas the InsP 3 R binding core and channel domain are highly conserved between InsP 3 R family members, the intervening ϳ1700-amino acid region is appreciably more variable and has been called the "modulatory" or "regulatory and coupling domain."
This designation is based on the presence of numerous loci for interaction with regulatory factors that influence the Ca 2ϩ release properties of the receptor. Moreover, because of the variability in sequence in this region, modulation can potentially occur in an InsP 3 R-specific manner. The most important regulator of InsP 3 R activity is undoubtedly Ca 2ϩ itself. Ca 2ϩ acts as a co-agonist to facilitate Ca 2ϩ release at low concentrations and inhibit channel activity at high concentrations (21, 22) . Numerous additional factors, such as the binding of proteins, interaction with adenine nucleotides, and phosphorylation by numerous kinases, can also significantly influence the activity of the receptor (for reviews, see Refs. 1 and 2). For example, our laboratory has recently demonstrated that phosphorylation by cyclic nucleotide-dependent protein kinases can greatly augment the activity of the InsP 3 R-1 (23, 24) * This work was supported by National Institutes of Health (NIH) Grants RO1-DK54568, R01-DE14756, and R01-DE16999 (to D. I. Y.). The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact. 1 Supported by NIDCR, NIH, Grant T32-DE07202. 2 To whom correspondence should be addressed. Tel.: 585-273-2154; E-mail:
David_Yule@urmc.rochester.edu.
(see Refs. [25] [26] [27] [28] [29] . This event results in enhanced Ca 2ϩ release and serves as a potentially important point of interaction between Ca 2ϩ and cAMP-mediated signaling. Interestingly, whereas both the peripherally expressed S2
Ϫ and neuronal S2 ϩ InsP 3 R-1 variant contain two identical consensus motifs for phosphorylation by cAMP-dependent protein kinase (PKA) (10, 30) (at Ser-1589 and Ser-1755), one of which is also a motif predicted to be phosphorylated by cGMP-dependent protein kinase (Ser-1755), mutagenesis studies indicated that the particular functionally important phosphorylation sites were different in the individual splice variants. Specifically, PKA-dependent phosphorylation of only Ser-1755 led to enhanced Ca 2ϩ release in the S2 ϩ form, whereas phosphorylation of both sites was functionally relevant in the S2 Ϫ form (23, 24) . Furthermore, only the S2 ϩ form was modulated following phosphorylation by cGMP-dependent protein kinase (23) . The S2 Ϫ InsP 3 R differs from the S2 ϩ form by the excision of 39 amino acids (Glu-1693 to Arg-1731) between the two phosphorylation sites (see Fig.  1A ). The structural or mechanistic grounds for this and other differences between the two splice variants, however, are presently unknown.
Of interest, sequence analysis of the S2 Ϫ InsP 3 R-1 indicates that the only striking difference from the S2 ϩ InsP 3 R-1 is the presence of a glycinerich motif (Gly-X-Gly-X-X-Gly) at aa 1688 -1732 (Fig. 1A ) (31) (32) (33) . This motif could potentially serve as a nucleotide binding fold and thus is suggestive of a role for S2 Ϫ -specific effects mediated by the binding of adenine nucleotides. Indeed, adenine nucleotides, in particular ATP, have marked effects on InsP 3 R activity. Low concentrations of ATP have been shown to enhance the activity of both InsP 3 R-1 and InsP 3 R-3 but interestingly not InsP 3 R-2 (34 -38) . High concentrations of ATP inhibit activity of all InsP 3 R. The latter observation reflects ATP competing with InsP 3 for binding to the receptor (39, 40) , whereas the former is thought to occur by binding of ATP to specific sites in the receptor. The effect of ATP to enhance Ca 2ϩ release has been proposed to occur by allosterically tuning the Ca 2ϩ sensitivity of the receptor to favor activation (37) . Nucleotide binding folds, based on the Gly-X-Gly-X-X-Gly motif (41) Ϫ InsP 3 R-1 splice variant, 39 amino acids are excised between Lys-1692 and Gly-1732. This event introduces a glycine-rich motif (Gly-X-Gly-X-X-Gly), which often forms a nucleotide binding motif referred to as ATPC. Mutation of the second Gly in the motif would be predicted to disrupt the nucleotide binding (see "Results and Discussion"). This mutation is subsequently referred to as change in ATPC (⌬ATPC). B, a schematic diagram of additional nucleotide binding sites in InsP 3 R-1. The ATPA site spans amino acids 1773-1780, and the ATPB site is between amino acids 2016 and 2021. To disrupt nucleotide binding in the ATPA site, Gly-1775 and Gly-1777 were mutated to Ala (⌬ATPA). Similarly, Gly-2018 was mutated to Ala to create ⌬ATPB. rated into the oligonucleotides used for PCR amplification. The PCR products were restriction enzyme-digested and ligated into pFN2A at the SgfI and PmeI sites. This creates a fusion construct with GST at the N terminus of the InsP 3 R-1 and a TEV protease recognition sequence in between to allow cleavage and removal of GST. WT S2 Ϫ InsP 3 R-1 and a construct with G1690A mutation in this region were created and were verified by sequencing. BL21 (DE3) pLysS cells (Promega, Madison, WI) were transformed with each DNA construct. Individual colonies were picked and grown overnight in 10 ml of Luria broth supplemented with ampicillin. The overnight cultures were added to 990 ml of Luria broth. The 1000-ml cultures were grown for 2 h at 37°C and 200 rpm. Protein production was induced by the addition of 1 ml of 0.1 M isopropyl 1-thio-␤-D-galactopyranoside (EMD Biosciences, San Diego, CA), and cultures were further incubated for 2 h. Cells were pelleted and lysed, and GST fusion protein was purified using a GST purification kit (BD Biosciences). This purified protein was then cleaved with TEV protease (Invitrogen), and GST was removed by running through a GST purification column. The GST fraction was bound to the glutathione column, whereas the InsP 3 R-1 protein immediately eluted off. Purified InsP 3 R-1 protein was concentrated using an Amicon Ultra-15 centrifugal filter device (Millipore Corp., Bedford, MA) and brought up to a final concentration of 0.5 mg/ml in 50 mM Tris buffer. Purified proteins were separated on 15% polyacrylamide gels and were either detected by BioSafe Coomassie Blue staining (Bio-Rad) or by immunoblotting with a monoclonal ␣-GST (Rockland, Gilbertsville, PA) antibody or a polyclonal antibody directed against the nonphosphorylated sequence flanking Ser-1755 (43) (kindly provided by Dr. S. Snyder). ATP Binding Assay-The fluorescent ATP analogue TNP-ATP (Molecular Probes, Inc., Carlsbad, CA) was used to measure binding of ATP to the purified InsP 3 R-1 protein fragments. TNP-ATP fluorescence increases upon binding to protein (44, 45) (excitation, 403 nm; emission, 546 nm). 1 mg of protein in 2 ml of 50 mM Tris-HCl was used for each assay. Increases in TNP-ATP fluorescence were detected using a PerkinElmer LS-5B luminescence spectrometer (Wellesley, MA). Increasing concentrations of TNP-ATP were added sequentially to cuvettes containing protein, and fluorescence was measured every second. Background fluorescence was determined by measuring TNP-ATP emission at various concentrations in Tris buffer alone. Net fluorescence for binding to protein was determined by subtracting background fluorescence. Normalized concentration-response relationships were created and fit with a logistic equation, and apparent EC 50 values were calculated using OriginPro software (OriginLab, Northampton, MA). ATP competition assays were performed identically to the standard TNP-ATP binding assay, except protein-induced fluorescence was measured in the presence of 10 mM Na-ATP.
MATERIALS AND METHODS

Mutagenesis
Creation of Stable Muscarinic M3 Receptor-expressing DT40-3KO Cells-3ϫ HA-tagged human M3R cDNA in pCDNA3.1 was obtained from the UMR cDNA resource center (available on the World Wide Web at www.cdna.org). MfeI-digested plasmid was introduced into DT40 cells lacking expression of all InsP 3 R types (38, 46) (DT40-3K0 cells) by nucleofection using program B23 and solution T as per the manufacturer's instructions (Amaxa, Inc.) to create the DT40-3KO-M3 stable cell line. After nucleofection, the cells were incubated in growth medium for 24 h prior to dilution in selection medium containing 2 mg/ml Geneticin (Invitrogen). Cells were then seeded into 96-well tissue culture plates at ϳ1000 cells/well and incubated in selection medium for at least 7 days. Wells exhibiting growth after the selection period were picked for expansion.
Transient Transfection of DT40-3KO Cells-For permeabilized cell studies, DT40-3KO cells were transfected by nucleofection, as described above. For concentration-response relationships in intact DT40-3KO-M3 cells, cells were transfected by electroporation at 350 V and 950 microfarads (4-mm gap cuvette). 2 ϫ 10 7 cells were co-transfected with 25 g of the InsP 3 R-1 cDNA, and 4 g of the red fluorescent protein plasmid pHcRed1-N1 (BD Biosciences). For forskolin-induced PKA potentiation assays, DT40-3KO cells were co-transfected with 25 g of the InsP 3 R-1 cDNA, 25 g of the mouse type 3 muscarinic receptor, and 4 g of the red fluorescent protein plasmid pHcRed1-N1 (BD Biosciences). Cells were incubated with DNA in 500 l of Opti-MEM medium (Invitrogen) on ice for 10 min. The cell/DNA mixture was electroporated, incubated on ice for 30 min, increased to 5 ml with Opti-MEM, and placed in a 5% CO 2 incubator at 39°C for 5 h. The cells were then centrifuged and resuspended in 12 ml of complete RPMI medium (Invitrogen). Transfection efficiency was typically ϳ20%. Experiments were performed within 32 h of transfection.
Transfection of HEK-293 Cells and Assessment of Phosphorylation-HEK-293 cells were plated onto 25-cm 2 culture flasks and allowed to grow to near confluence. Cells were transfected with 5 g of each S2
Ϫ InsP 3 R-1 DNA construct by using the Lipofectamine reagent (Invitrogen) as per the manufacturer's instructions. The following day, batches of cells were treated in the presence or absence of 20 M forskolin for 10 min, aspirated from flasks, lysed in a buffer containing 50 mM Tris-HCl, 250 mM NaCl, 50 mM NaF, 5 mM EDTA, 0.1% Triton, and 1 mM Complete Protease inhibitor tablet (Roche Applied Science) at pH 7.4. InsP 3 R were immunoprecipitated with a polyclonal ␣-InsP 3 R-1 antibody that recognizes amino acids 2731-2749 of InsP 3 R-1 (␣-InsP 3 R-1). Immunoprecipitates were separated on 5% SDS gels, transferred to nitrocellulose, and then probed with either a polyclonal antibody raised against the sequence flanking Ser-1755 of InsP 3 R-1 (␣-S1755) or a polyclonal antibody raised against a similar region that specifically recognizes the phosphorylated state of Ser-1755 (␣-S1755P). Blots that were probed with ␣-S1755P were stripped and reprobed with the ␣-S1755 antiserum to confirm the presence and relative quantity of the InsP 3 R-1.
Digital Imaging of [Ca 2ϩ ] i in Intact Cells-Transfected DT40-3KO cells were washed once in a HEPES-buffered physiological saline solution (HEPES-PSS) containing 5.5 mM glucose, 137 mM NaCl, 0.56 mM MgCl 2 , 4.7 mM KCl, 1 mM Na 2 HPO 4 , 10 mM HEPES (pH 7.4), 1.2 mM CaCl 2 , and 1% (w/v) bovine serum albumin. Cells were then resuspended in bovine serum albumin HEPES-PSS with 1 M Fura-2 (AM) (Teflabs Inc., Austin, TX), placed on a 15-mm glass coverslip in a low volume perfusion chamber, and allowed to adhere for 30 min at room temperature. Cells were perfused continuously for 10 min with HEPES-PSS before experimentation to allow complete Fura-2 de-esterification. A field of cells for each experiment was chosen that contained a wide range of transfection efficiency based upon the intensity of red fluorescence emitted when excited at 560 nm. Individual cells that had emission gray levels between 1500 and 2500 were subsequently chosen to standardize expression levels. [Ca 2ϩ ] i imaging was performed essentially as described previously, using an inverted epifluorescence Nikon microscope with a ϫ40 oil immersion objective lens (numerical aperture, 1.3). Cells were excited alternately with light at 340-nm and 380 Ϯ 10-nm bandpass filters (Chroma, Rockingham, VT) using a monochrometer (TILL Photonics, Pleasanton, CA). Fluorescence images were captured and digitized with a digital camera driven by TILL Photonics software. Images were captured every 2 s with an exposure of 10 ms and 4 ϫ 4 binning. 340/380 ratio images were calculated online and stored immediately to a hard disk.
Permeabilized Cell Ca 2ϩ Measurements-InsP 3 R expression constructs along with a nuclear targeted HcRed expression construct (pHcRed-nuc; BD Biosciences, Palo Alto, CA) were introduced into DT40-3KO cells using nucleofector protocol B23 and solution T (Amaxa Biosystems, Gaithersburg, MD). Concentration-response Relationships and Statistical Analysis-The effects of treatment were determined by normalizing the peak change in fluorescence ratio by stimulation following forskolin exposure to that of stimulation in control HEPES-PSS. Thus, pooled data represent a normalized -fold increase over control for the treated trial. Multiple cells were analyzed in each experiment. This mean value from an individual experiment was pooled and averaged with multiple experimental runs from at least three different batches of transfected cells. Where statistical significance is indicated, two-tailed heteroscedastic t tests were performed. p values of Ͻ0.05 were considered to indicate statistical significance and are denoted by an asterisk in the figures.
Normalized ⌬F concentration-response relationships were fit with the following logistic Equation 1,
where ⌬F represents the change in fluorescence normalized to the maximal response, C is agent concentration; EC 50 is the concentration where the response is half of maximum, and Slope⌬F is a slope factor related to the Hill coefficient.
RESULTS AND DISCUSSION
Binding of ATP to the "ATPC" Site in S2
Ϫ InsP 3 R-1-cDNA encoding fusion proteins of GST and aa 1574 -1765 of the S2 Ϫ InsP 3 R-1 were constructed, and the proteins were expressed and purified from Escherichia coli. The cDNAs were designed to include the putative ATPC site (aa 1688 -1693, Gly-Tyr-Gly-Glu-Lys-Gly) unique to S2 Ϫ InsP 3 R-1 and include the Ser-1755 phosphorylation site as well as sufficient flanking sequence to obtain stable proteins. The latter consideration was based on previous observations by Maes et al. (33) that small receptor fragments bound nucleotides poorly. The tertiary structure of nucleotide binding proteins predicts that the Gly-X-Gly-X-X-Gly motif facilitates binding of ATP by forming a pocket that allows a favorable interface for hydrogen bonding and further favors interaction of the negatively charged pyrophosphate moiety of ATP with protein. The second glycine residue is especially important in this regard, and substitution of this residue with any amino acid with a side chain is predicted to interfere with this interaction (41) . Indeed, several naturally occurring mutations in this motif lead to disease states. These include mutations in the insulin receptor, p21, and H-Ras-1 (41, 47, 48) . We therefore also designed a construct encoding a GST fusion of the same region of the S2 Ϫ InsP 3 R but encoding a mutation of the second glycine in the Gly-X-Gly-X-X-Gly motif to alanine (G1690A; Gly-Tyr-Ala-Glu-Lys-Gly), which we referred to as GST-⌬ATPC. Following purification by affinity chromatography and further purification by size exclusion, the fusion proteins were separated by SDS-PAGE and either transferred to nitrocellulose for Western analysis or stained with Coomassie Blue. Fig. 2A (top) shows a sample of GST-ATPC (lane 1) or GST-⌬ATPC (lane 2) stained with Coomassie Blue and confirms that the proteins migrate at the predicted molecular mass of ϳ44.5 kDa. The middle panel shows that antiserum raised against the sequence flanking Ser-1755 recognizes the GST-ATPC and GST-⌬ATPC. Similarly, ␣-GST antiserum also recognizes proteins of identical weight. Following cleavage with TEV protease, the protein fraction retained on the column from either construct migrates in a fashion predicted for GST alone (ϳ27 kDa; lanes 3 and 4; top) and is recognized by ␣-GST antiserum (lanes 3 and 4, bottom) but not ␣-S1755 (lanes 3  and 4, middle) . Conversely, the cleaved, eluted fraction runs at a mass predicted for the ATPC site protein (ϳ17.5 kDa; lanes 5, top) or ⌬ATPC (lane 6, top) and is recognized by ␣-S1755 antiserum (lanes 5 and 6; ATPC or ⌬ATPC, respectively; middle) but not ␣-GST antiserum ( lanes 5 and 6, bottom) .
Next, experiments were performed to judge nucleotide binding to ATPC following cleavage and purification from GST. This was assessed by monitoring the binding of TNP-ATP, a derivative of ATP that exhibits enhanced fluorescence and a spectral shift in maximal fluorescence when bound to peptides (44, 45) . Increasing concentrations of TNP-ATP in the presence of 1 mg of ATPC resulted in an increase in fluorescence as shown in Fig. 2B (filled circles) (corrected for the increase in fluorescence in the absence of protein in all cases). The EC 50 for the enhanced fluorescence was 300 Ϯ 10 nM TNP-ATP (n ϭ 11 preparations of protein performed in triplicate). The increase in TNP-ATP fluorescence was completely abrogated by competition with 10 mM ATP incubated prior to the addition of the TNP-ATP as shown in the filled triangles in Fig. 2B (n ϭ 4) . These data establish that the ATPC site is indeed capable of binding ATP with relatively high affinity and presumably indicate that in situ, the motif binds ATP in the S2 Ϫ InsP 3 R.
Importantly, as shown in Fig. 2B (open circles) , the single point mutation in the ATPC site construct (⌬ATPC) completely negates binding of TNP-ATP to ATPC. Experiments were also performed to confirm ATP binding to fragments of the InsP 3 R-1 containing the ATPA and ATPB sites and importantly to determine if similar Gly 3 Ala mutations abrogated binding to these sites. As shown in Fig. 2, C and D, for the ATPA and ATPB sites, respectively, TNP-ATP bound to both fragments with high affinity (EC 50 ϭ 53 Ϯ 4 nM for ATPA; EC 50 71 Ϯ 4 nM for ATPB (n ϭ 3). Protein fragments were again constructed containing Gly 3 Ala mutations within the respective nucleotide binding folds. In the case of the ATPA site, which contains two putative binding folds, both Gly-1775 and Gly-1777 were mutated to Ala, whereas in the ATPB site, a Gly-2018 3 Ala construct was made. As shown in Fig. 2, C and D , respectively, the Gly 3 Ala mutation in either site completely abolished binding of TNP-ATP.
It should be noted, however, that it is difficult to make a definitive conclusion regarding the affinity of the ATPC site in vivo or to make comparisons with the ATPA and ATPB sites. This is primarily because the apparent affinity observed is probably only relevant in the structural context of this particular fragment and secondarily because the affinity of TNP-ATP for nucleotides has been reported to be higher than ATP itself (44) . 2) and were recognized by antiserum recognizing InsP 3 R-1 or GST (middle and bottom, respectively). Following cleavage of GST, the fraction retained on the column (lanes 3 and 4) migrates as expected for GST and is recognized by ␣-GST (bottom) but not ␣-S1755 (middle). Conversely, the flow through from the column (lanes 5 and 6) migrates as expected for the ATPC/⌬ATPC fragment. This fragment was not recognized by ␣-GST (middle) but was recognized by ␣-S1755 (bottom). B, the binding of ATP to ATPC was assessed by monitoring TNP-ATP fluorescence as described under "Materials and Methods." TNP-ATP bound specifically to ATPC with an EC 50 ϭ 300 Ϯ 10 nM (filled circles). This specific binding was completely inhibited by prior incubation with 10 mM ATP (filled triangles). TNP-ATP did not bind to ⌬ATPC (open circles). C, TNP-ATP bound with high affinity to the ATPA site consisting of a fragment of S2 Ϫ InsP 3 R-1 corresponding to amino acids 1756 -1850 (filled squares; EC 50 ϭ 53 Ϯ 4 nM). TNP-ATP failed to bind to ⌬ATPA (open squares). D, TNP-ATP bound with high affinity to the ATPB site consisting of a fragment of S2 stimulated with a range of CCh concentrations (0.3-100 M) for 60 s, followed by a 5 min wash-out period prior to the next stimulation. Fig. 3A shows a representative trace for DT40-3KO-M3 cells expressing WT S2
Assessment of the Physiological Role of ATP Binding to ATPC in S2
Ϫ InsP 3 R-1. A significant increase in [Ca 2ϩ ] i was typically observed at 0.3 M CCh, and the initial peak reached a maximum value between 1 and 10 M. In the majority of cells, the profile of response consisted of an initial peak, dependent on the concentration of agonist, followed by regular sinusoidal oscillations of fairly constant frequency. In contrast, DT40-3KO-M3 cells expressing ⌬ATPC were much less sensitive to CCh than WT as shown in Fig. 3B . An estimate of the relative sensitivity of the constructs was made by fitting the normalized concentration-response relationships. As shown in Fig. 3E , the apparent EC 50 for CCh-evoked Ca 2ϩ release was ϳ40-fold higher for WT versus ⌬ATPC (0.2 Ϯ 0.1 M versus 8.0 Ϯ 0.1 M CCh WT versus ⌬ATPC, respectively). Notwithstanding the shift in sensitivity, the maximal peak response attainable following stimulation with CCh was not significantly different between constructs (maximum ⌬ fluorescence 0.54 Ϯ 0.04 ratio units and 0.61 Ϯ 0.07 ratio units of WT versus ⌬ATPC respectively; see Fig. 3F for pooled data) . Similarly, although higher concentrations of CCh were required to generate robust Ca 2ϩ signals in ⌬ATPC-expressing cells ([CCh] Ͼ 1 M), the oscillation frequency and profile of response were not different from WT S2 Ϫ InsP 3 R-1 at these concentrations (see pooled data in Fig. 3F ). These data indicate that the apparent decreased sensitivity of ⌬ATPC is unlikely to be as a result of gross alteration of receptor function or marked differences in receptor expression.
Next, experiments were performed to assess if this observation was unique to effects on the S2 Ϫ ATPC site. Constructs were designed with similar mutations (Gly 3 Ala) to disrupt ATP binding in the ATPA (referred to as ⌬ATPA) and ATPB sites (referred to as ⌬ATPB) as described under "Materials and Methods." Representative traces are shown for the ⌬ATPA mutant and ⌬ATPB mutant in Fig. 3 , C and D, respectively, and the pooled data are included in Fig. 3 , E-G. Mutation of either of these sites did not alter the apparent sensitivity (EC 50 ϭ 0.2 Ϯ 0.1 M CCh versus 0.2 Ϯ 0.1 M CCh; ⌬ATPA versus ⌬ATPB, respectively; see Fig. 3E and compare with WT), the maximal peak response (maximal ⌬ fluorescence 0.64 Ϯ 0.06 versus 0.61 Ϯ 0.07; ⌬ATPA versus ⌬ATPB, respectively; Fig. 3F ), or the profile/oscillation characteristics (Fig. 3G ) of the Ca 2ϩ response with respect to WT S2 Ϫ InsP 3 R-1. Taken together, these data again indicate that only the sensitivity, not the absolute efficacy, of Ca 2ϩ release was specifically altered by the ⌬ATPC mutation but not similar mutations in other ATP bind- Ϫ InsP 3 R-1 construct, markedly less sensitive to CCh stimulation. C, a representative trace from cells expressing the ⌬ATPA construct, which, in contrast to ⌬ATPC, shows a concentration versus response relationship indistinguishable from WT. D, a representative trace from cells expressing ⌬ATPB; similarly, the concentration versus response relationship is similar to WT. E, the initial peak of each response (as an indication of Ca 2ϩ release) was normalized to maximal response attained in a particular cell and pooled data used to create a concentration versus response relationship for each construct. The fit for each data set is shown and illustrates that only ⌬ATPC is altered when compared with WT. F, the maximal change in fluorescence attained with each construct, which was not different, indicating a change in sensitivity of release but not efficacy. G, the oscillation frequency for each construct through the range of CCh concentrations used. In WT, ⌬ATPA, and ⌬ATPB, the oscillation frequency is not markedly modulated by CCh concentration. In ⌬ATPC, although the threshold for the generation of regular oscillations is higher than WT, the profile of the response is not markedly different.
ing sites. Thus, this observation probably indicates an important role for binding of ATP, specifically to the ATPC site in S2
Ϫ InsP 3 R-1, even on the background of expression of intact ATPA and ATPB sites. Of interest, whereas it is known that binding of ATP to the ATPA and B sites can modulate InsP 3 R-1 activity, in contrast to mutation of the ATPC site, no effect on global Ca 2ϩ signaling was observed with either single site mutation. These data have several implications; importantly, they indicate that the ATPC site has a unique role in modulating S2
Ϫ InsP 3 R-1 activity that can be dissociated from, and not substituted for, by the other nucleotide binding sites. Second, at physiological levels of ATP, it would appear that either an intact ATPA or ATPB site is sufficient to mediate the remaining effects of nucleotide binding on InsP 3 R-1 activity. This idea would be consistent with the affinities of these sites being high and essentially equal (ϳ1 M for ATP (33) or ϳ50 -70 nM for TNP-ATP (Fig. 2) ) when measured in the context of GST fusion proteins derived specifically from the InsP 3 R-1 (33) . (Fig. 4B) , the cytosolic indicator was released by permeabilization with ␤-escin, and the transfected cells were identified by retention of nuclear fluorescence of HcRed-nuc (Fig.  4D) . This leaves the remaining indicator trapped in a perinuclear compartment characteristic in DT40 cells of the endoplasmic reticulum (Fig. 4C) Following stimulation with a threshold concentration of CCh, subsequent incubation with forskolin results in a dramatically augmented increase in [Ca 2ϩ ] i to an identical concentration of CCh ( Fig. 5A ; see Ref. 23 ). In marked contrast, cells expressing ⌬ATPC InsP 3 R-1 failed to exhibit enhanced responses following forskolin treatment (Fig. 5B) . Furthermore, DT40-3KO cells expressing receptor constructs on the ⌬ATPC background with mutations in either single PKA phosphorylation site (S1589A or S1755A) were also refractory to any effects of raising cAMP, indicating involvement of both phosphorylation sites (pooled data in Fig. 5E ). In addition, this effect was specific for the ATPC site, since raising cAMP resulted in an enhancement of the Ca 2ϩ signal in DT40-3K0 cells expressing either ⌬ATPA (Fig. 5, C and E) or ⌬ATPB (Fig. 5, D and E) to a degree that was not significantly altered with respect to WT.
Foremost, these data demonstrate that nucleotide binding to the ATPC site plays an important role in defining the susceptibility of the S2-InsP 3 R-1 to regulation by PKA. Secondarily, however, this striking lack of PKA regulation in the ⌬ATPC mutant InsP 3 R may also, at least in part, explain the decreased sensitivity of the ⌬ATPC mutant observed in Fig. 3B . To support this idea, the assumptions must be made that any constitutive functional effect of PKA phosphorylation under resting conditions is not present in the ⌬ATPC mutant and also absent in permeabilized cells. The absence of effects in the Ca 2ϩ release assay could occur because permeabilization results in loss of PKA or, alternatively, because the effective infinite volume of the cytoplasm created by permeabilization results in insufficient levels of cAMP to activate any remaining anchored kinase. The decreased sensitivity of the ⌬ATPC mutant is consistent with data indicating that a S2 Ϫ InsP 3 R-1 construct containing mutations at S1589A and S1755A (referred to in Ref. 24 as the "AA" construct), which also is not subject to phosphoregulation by PKA, is characterized by an ϳ8-fold right shift in the sensitivity of agonist-induced Ca 2ϩ release when compared with WT S2 Ϫ InsP 3 R-1-expressing cells (24) . This difference in sensitivity is consistent with a portion of the WT InsP 3 R-1 but not the AA mutant being phosphorylated at these sites under basal conditions (24) . Notwithstanding this idea, it should, however, be noted that the absence of regulation by PKA of ⌬ATPC under basal conditions may not account in full for the decrease in the sensitivity of Ca 2ϩ release observed in cells expressing this construct. Indeed, these data do not necessarily exclude the possibility that the decrease in sensitivity and loss of phosphoregulation in ⌬ATPC mutants under basal conditions are not, in fact, causally associated. In this scenario, the increase in sensitivity of the receptor may The potentiation was also lost in cells expressing ⌬ATPC constructs in which individual PKA phosphorylation sites were mutated from Ser to Ala (A-⌬ATPC-S, S1589A/G1690A/Ser-1755; S-⌬ATPC-A, Ser-1589/G1690A/S1755A).
